Quick preparation of ABO-incompatible living donor liver transplantation for acute liver failure

被引:12
作者
Lee, Wei-Chen [1 ,2 ]
Cheng, Chih-Hsien [1 ,2 ]
Lee, Chen-Fang [1 ,2 ]
Hung, Hao-Chien [1 ,2 ]
Lee, Jin-Chiao [1 ,2 ]
Wu, Tsung-Han [1 ,2 ]
Wang, Yu-Chao [1 ,2 ]
Wu, Ting-Jung [1 ,2 ]
Chou, Hong-Shiue [1 ,2 ]
Chan, Kun-Ming [1 ,2 ]
机构
[1] Chang Gung Mem Hosp, Dept Gen Surg, Div Liver & Transplantat Surg, 5 Fu Hsing St, Taoyuan, Linkou, Taiwan
[2] Chang Gung Univ, Coll Med, Taoyuan, Taiwan
关键词
ABO-incompatibility; bortezomib; living donor liver transplantation; rituximab; PLASMA-CELLS; RITUXIMAB; DESENSITIZATION; BORTEZOMIB; PROTOCOL; DISEASE;
D O I
10.1111/ctr.14555
中图分类号
R61 [外科手术学];
学科分类号
摘要
Acute liver failure is life-threatening and has to be treated by liver transplantation urgently. When deceased donors or ABO-compatible living donors are not available, ABO-incompatible (ABO-I) living donor liver transplantation (LDLT) becomes the only choice. How to prepare ABO-I LDLT urgently is an unsolved issue. A quick preparation regimen was designed, which was consisted of bortezomib (3.5 mg) injection to deplete plasma cells and plasma exchange to achieve isoagglutinin titer <= 1: 64 just prior to liver transplantation and followed by rituximab (375 mg/m(2)) on post-operative day 1 to deplete B-cells. Eight patients received this quick preparation regimen to undergo ABO-I LDLT for acute liver failure from 2012 to 2019. They aged between 50 and 60 years. The median MELD score was 39 with a range from 35 to 48. It took 4.75 +/- 1.58 days to prepare such an urgent ABO-I LDLT. All the patients had successful liver transplantations, but one patient died of antibody-mediated rejection at post-operative month 6. The 3-month, 6-month, and 1-year graft/patient survival were 100%, 87.5%, and 75%, respectively. In conclusion, this quick preparation regimen can reduce isoagglutinin titers quickly and make timely ABO-I LDLT feasible for acute liver failure.
引用
收藏
页数:7
相关论文
共 35 条
  • [1] Desensitization in kidney transplantation: review and future perspectives
    Abu Jawdeh, Bassam G.
    Cuffy, Madison C.
    Alloway, Rita R.
    Shields, Adele Rike
    Woodle, E. Steve
    [J]. CLINICAL TRANSPLANTATION, 2014, 28 (04) : 494 - 507
  • [2] Chang Alexander T, 2009, Transplant Rev (Orlando), V23, P191, DOI 10.1016/j.trre.2009.06.002
  • [3] Bortezomib: A New Promising Therapy for Early Antibody-Mediated Rejection After Liver Transplantation?
    Chedid, Marcio F.
    Rodrigo, Emilio
    [J]. TRANSPLANTATION DIRECT, 2019, 5 (10):
  • [4] 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejectio
    Demetris, A. J.
    Bellamy, C.
    Hubscher, S. G.
    O'Leary, J.
    Randhawa, P. S.
    Feng, S.
    Neil, D.
    Colvin, R. B.
    McCaughan, G.
    Fung, J. J.
    Del Bello, A.
    Reinholt, F. P.
    Haga, H.
    Adeyi, O.
    Czaja, A. J.
    Schiano, T.
    Fiel, M. I.
    Smith, M. L.
    Sebagh, M.
    Tanigawa, R. Y.
    Yilmaz, F.
    Alexander, G.
    Baiocchi, L.
    Balasubramanian, M.
    Batal, I.
    Bhan, A. K.
    Bucuvalas, J.
    Cerski, C. T. S.
    Charlotte, F.
    de Vera, M. E.
    ElMonayeri, M.
    Fontes, P.
    Furth, E. E.
    Gouw, A. S. H.
    Hafezi-Bakhtiari, S.
    Hart, J.
    Honsova, E.
    Ismail, W.
    Itoh, T.
    Jhala, N. C.
    Khettry, U.
    Klintmalm, G. B.
    Knechtle, S.
    Koshiba, T.
    Kozlowski, T.
    Lassman, C. R.
    Lerut, J.
    Levitsky, J.
    Licini, L.
    Liotta, R.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 (10) : 2816 - 2835
  • [5] Impact of Rituximab Desensitization on Blood-Type-Incompatible Adult Living Donor Liver Transplantation: A Japanese Multicenter Study
    Egawa, H.
    Teramukai, S.
    Haga, H.
    Tanabe, M.
    Mori, A.
    Ikegami, T.
    Kawagishi, N.
    Ohdan, H.
    Kasahara, M.
    Umeshita, K.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 (01) : 102 - 114
  • [6] Present status of ABO-incompatible living donor liver transplantation in japan
    Egawa, Hiroto
    Teramukai, Satoshi
    Haga, Hironori
    Tanabe, Mnoru
    Fukushima, Masanori
    Shirnazu, Motohide
    [J]. HEPATOLOGY, 2008, 47 (01) : 143 - 152
  • [7] B-cell surface marker analysis for improvement of rituximab prophylaxis in ABO-incompatible adult living donor liver transplantation
    Egawa, Hiroto
    Ohmori, Katsuyuki
    Haga, Hironori
    Tsuji, Hiroaki
    Yurugi, Kirniko
    Miyagawa-Hoyashino, Aya
    Oike, Fumitaka
    Fukuda, Akinari
    Yoshizawa, Jun
    Takada, Yasutsugu
    Tanaka, Koichi
    Maekawa, Taira
    Ozawa, Kazue
    Uemoto, Shinji
    [J]. LIVER TRANSPLANTATION, 2007, 13 (04) : 579 - 588
  • [8] Optimal dosage regimen for rituximab in ABO- incompatible living donor liver transplantation
    Egawa, Hiroto
    Umeshita, Koji
    Uemoto, Shinji
    [J]. JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2017, 24 (02) : 89 - 94
  • [9] Bioartificial liver support systems for acute liver failure: A systematic review and meta-analysis of the clinical and preclinical literature
    He, Yu-Ting
    Qi, Ya-Na
    Zhang, Bing-Qi
    Li, Jian-Bo
    Bao, Ji
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2019, 25 (27) : 3634 - 3648
  • [10] Successful Kidney Transplantation After Stepwise Desensitization Using Rituximab and Bortezomib in a Highly HLA-Sensitized and ABO Incompatible High Titer Patient
    Inui, Masashi
    Miyazato, Tomonori
    Furusawa, Miyuki
    Okumi, Masayoshi
    Omoto, Kazuya
    Ishida, Hideki
    Tanabe, Kazunari
    [J]. TRANSPLANTATION DIRECT, 2016, 2 (08): : E92